Verapamil Lowers Glucose Levels.

Remy

Administrator
Looky here, @IrisRV! A very versatile drug, this verapamil...

A new University of Alabama at Birmingham research paper published in the journal Diabetes Research and Clinical Practice shows for the first time that there is an association of verapamil use and lower fasting glucose levels in humans with diabetes. It is a promising finding at UAB, where the Comprehensive Diabetes Center is currently conducting a first-of-its-kind, JDRF-funded clinical trial using verapamil, a drug that researchers in the School of Medicine have shown completely reverses the disease in mice models.

Yulia Khodneva M.D., Ph.D., a research associate and postdoctoral scholar in UAB's Division of Preventive Medicine and junior member of the Comprehensive Diabetes Center, examined the association of calcium channel blockers and verapamil use with fasting serum glucose among almost 5,000 adults with diabetes who were part of the REGARDS study. The Reasons for Geographic and Racial Differences in Stroke project, sponsored by the National Institutes of Health, is a national study focusing on learning more about the factors that increase a person's risk of having cardiovascular disease.

The sample of diabetic adults included 1,484 calcium channel blocker users, of whom 174 were verapamil users. The findings showed that calcium channel blocker users had 5 mg/dL lower serum glucose compared to non-users. Verapamil users had on average 10 mg/dL lower serum glucose compared to calcium channel blocker non-users. And the numbers showed a substantially greater difference among insulin users who also took verapamil. Verapamil users who took insulin in combination with oral medication had a 24 mg/dL lower serum glucose, and verapamil users who took insulin alone to manage their diabetes showed a 37 mg/dL lower serum glucose.

"This is a cross-sectional observational study unlike the current prospective randomized UAB verapamil clinical trial, so we can't infer causal relationship between using verapamil and lower glucose levels; but we can say there is an association with lower glucose levels, and that is absolutely encouraging," Khodneva said.
Khodneva says the findings in the final subgroup, which used insulin alone and included participants who had mostly Type 1 or severe Type 2 diabetes, were quite striking.

"The change in glucose for that group compared to those not taking verapamil -- 37 mg/dL -- is almost four times higher than when you look at the whole sample of diabetic adults," Khodneva said. "That made us think that verapamil is predominantly active for participants who have Type 1 diabetes or those with Type 2 diabetes who have really damaged beta cells. There seems to be something that works on the structural level, especially for those who have stronger beta-cell damage."

"Dr. Khodneva has done a tremendous job analyzing these large data sets and discovering for the first time that verapamil use is associated with lower glucose levels in patients with diabetes," said Anath Shalev, M.D., director of UAB's Comprehensive Diabetes Center and principal investigator of the verapamil clinical trial. "Strikingly, the observed difference in glucose levels is comparable to an approximately 1 percent reduction in HbA1C and to what would be expected from the addition of an approved diabetes drug. Moreover, the large difference in glucose levels especially in the groups taking insulin is consistent with our underlying hypothesis that verapamil promotes functional beta-cell mass."

UAB announced its verapamil clinical trial in November 2014 and began enrolling patients in January 2015. The first results that will assess verapamil's effectiveness on Type 1 diabetes are still approximately 18 months away.

The trial is testing an approach different from any current diabetes treatment by focusing on promoting pancreatic beta cells, which produce insulin the body needs to control blood sugar. UAB scientists have proved through years of research that high blood sugar causes the body to overproduce a protein called TXNIP, which is increased within the beta cells in response to diabetes, but had never previously been known to be important in beta-cell biology. Too much TXNIP in the pancreatic beta cells leads to their death and thwarts the body's efforts to produce insulin, thereby contributing to the progression of diabetes.

But UAB scientists have also uncovered that verapamil, which is widely used to treat high blood pressure, irregular heartbeat and migraine headaches, can lower TXNIP levels by decreasing calcium concentration in the beta cells -- to the point that, when mouse models with established diabetes and blood sugars above 300 milligrams per deciliter were treated with verapamil, the disease was eradicated.
/1002721/ScienceDaily_Mobile_Middle_Rectangle

Story Source:
The above post is reprinted from materials provided by University of Alabama at Birmingham. Note: Materials may be edited for content and length.
/story_source

Journal Reference:
  1. Yulia Khodneva, Anath Shalev, Stuart J. Frank, April P. Carson, Monika M. Safford. Calcium channel blocker use is associated with lower fasting serum glucose among adults with diabetes from the REGARDS study. Diabetes Research and Clinical Practice, 2016; DOI: 10.1016/j.diabres.2016.01.021
 

IrisRV

Well-Known Member
Whoa! Who knew? I wonder what my blood glucose would be if I hadn't been taking verapamil for the past couple of years. :nailbiting:

I wonder if my doc would be willing to increase my verapamil based on this and the fact that I've recently developed hypertension. My current dosage is relatively low.
 

Merida

Well-Known Member
Thanks for the important info. My blood sugar readings have been up and down. Now, looks like I too am just developing high blood pressure. Hmmm.
 

RuthAnn

Well-Known Member
It does have some possible side effects, though.

  • Blue lips and fingernails
  • blurred vision
  • burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
  • chest pain
  • confusion
  • coughing that sometimes produces a pink frothy sputum
  • difficult, fast, noisy breathing, sometimes with wheezing
  • dizziness, faintness, or lightheadedness when getting up from a lying or sitting position suddenly
  • increased sweating
  • lightheadedness, dizziness, or fainting
  • pale skin
  • shortness of breath
  • slow or irregular heartbeat
  • sore throat
  • sweating
  • swelling in legs and ankles
  • unusual tiredness or weakness
Rare
  • Chills
  • cold sweats
  • feeling of warmth
  • redness of the face, neck, arms and occasionally, upper chest
Some verapamil side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:
More common
  • Difficulty having a bowel movement (stool)
  • headache
Less common
  • Acid or sour stomach
  • belching
  • difficulty in moving
  • heartburn
  • indigestion
  • joint pain
  • muscle aching or cramping
  • muscle pains or stiffness
  • nausea
  • rash
  • stomach discomfort, upset, or pain
  • trouble sleeping
  • unusual drowsiness, dullness, tiredness, weakness, or feeling of sluggishness
  • swollen joints
Immunologic

Immunologic side effects have included infection (up to 12.1%).
Respiratory

A 26-year-old man with rheumatic heart disease, mitral stenosis, and supraventricular tachycardia became apneic following a 5 mg intravenous bolus of verapamil. His heart rhythm at the time was supraventricular tachycardia at 290 beats per min; his blood pressure is not reported. The patient responded to assisted ventilation, oxygen, and DC cardioversion. The authors of this case report have located two other such cases, one of which had "stable hemodynamics," but died due to intravenous verapamil-associated acute respiratory arrest.

A 66-year-old woman with a 10-year history of hypertension and bronchial asthma was switched from immediate-release verapamil to sustained-release verapamil. The patient developed dyspnea, cough, and wheezing after taking the first tablet. The patient experienced similar reactions on three subsequent occasions with verapamil sustained-release administration.[Ref]
Respiratory side effects have included upper respiratory infection (up to 5.4%), pharyngitis (up to 3%), sinusitis (up to 3%), rhinitis (up to 2.7%), and dyspnea (up to 1.4%). Extremely rare cases of respiratory arrest have been associated with the use of intravenous verapamil. The mechanism is unknown. An acute asthma attack associated with sustained-release verapamil has been reported. Dyspnea has also been reported during open trials/postmarketing experience.[Ref]
 

Get Our Free ME/CFS and FM Blog!



Forum Tips

Support Our Work

DO IT MONTHLY

HEALTH RISING IS NOT A 501 (c) 3 NON-PROFIT

Shopping on Amazon.com For HR

Latest Resources

Top